TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change from baseline 20m-sprint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in the PSA-PIM Drug Burden Index (DBI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prediction of macrosomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurotoxicity as measured by FACT-NTX
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Modified total neuropathy score (mTNS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mobility score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Insertion torque curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in blood cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in BMI (body mass index) Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentration of MMP8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentration of MMP9
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentration of IL1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentration of IL6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentration of IL8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentration of IL17
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Chronic post surgical pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in MFM-32 total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of the cerebellar cognitive-affective syndrome scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Treatment-emergent Serious Adverse Events (TE-SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Chemotherapy-Induced Peripheral Neuropathy Assessment Tool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Response of the tumor to electrochemotherapy according to RECIST criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Higher mean heart rate variability (HRV) during a discrimination stressor task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Higher quality sleep for CSPs
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Increased job satisfaction for CSPs
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Intradialytic hypotension (IDH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Non-serious Adverse Events (Non-SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients with confirmed objective response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of disease progression free survival
Endpoint domain: Mortality/survival
Primary endpoint: Electrotactile BCI system accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor Imagery BCI system accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IRAF reporting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours Post-dose (AUC0-24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent Plasma Terminal Elimination Half-life (t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Boston carpal tunnel questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in serum hemoglobin A1c level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concordance between AI-based and laparoscopic total small bowel length measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Detection rate of early cancer and precancerous lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: AUC last of DWP14012
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of DWP14012
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance with hospital guidelines for antibiotic treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Combined quantification of measles-specific markers of T-cell-mediated immunity and B-cell-mediated immunity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants with negative cultures and negative NAAT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Completion of planned course of intravenous antibiotics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in emotion regulation (overall)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Antiphospholipid antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Biochemical blood analysis (uric acid)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of participants with dose modifications
Endpoint domain: Adverse events/effects
Primary endpoint: Dose intensity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in left ventricular mass to volume ratio (LVMV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of treatment-emergent adverse events (TEAEs and SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Numeric Rating Score (NRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion with viral load suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average change in best corrected visual acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: V̇O2 peak agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline sugar-sweetened beverages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Persistent Post-Operative Opioid Use
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of coronary microcirculation dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in comfort
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Anxiety levels measured by Hamilton Anxiety Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Boezzart bleeding score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with ≥1 positive surgical margins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean number of positive surgical margins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Binding of Pseudomonas aeruginosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prevalence of SNPs associated with autophagy deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: cervical stabilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lumbar stabilization grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sportive performance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Duration of QTc
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: infants meeting the Minimum Dietary Diversity (MDD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mothers meeting the Minimum Dietary Diversity for women (MDD-W)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mothers scoring >66% on the maternal health literacy inventory in pregnancy (MHELIP) scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of patients referred to an MBS program
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of new prescriptions of an FDA-approved pharmaceutical for obesity management
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in weight trajectory during 18-month post-intervention follow-up period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wang bronchiolitis score change by percentage from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Wang bronchiolitis score of 0 in proportion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Wang bronchiolitis score total score < 5 points
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Capability for enrollment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility of the randomization processes
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: How2trak compliance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Frontal plan projection angle evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Single leg squat test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viscoelastic properties of muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in BK channel gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Professional Quality of Life Scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cancer-treatment-related symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activities related to the pursuit of life goals
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Dosimetric metrics comparison
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Irisin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Health-Related Quality of Life (HRQoL) status
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Drug Consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: diagnostic accuracy of pulsed fluoroscopy retrograde urethrogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: diagnostic accuracy of pulsed traditional retrograde urethrogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Global Tolerance Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Difference in WOMAC score total
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Major Pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of involved margins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Increase in I-MEDAS score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Bruising
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change of the sum of MDS-UPDRS I-III from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: ≥50% decline in Prostate-specific antigen value (PSA50)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood concentration of androgen hormone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Ovulatory dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Changes in mean daily Heart Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in mean Respiratory Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mother's quality of life assessed by the WHOQoL-BREF
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Prevalence of EVB Viremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cardiotropic Virus Detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Maternal Immune Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Dynamic changes in StO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with helminth infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of participants with SARS-CoV-2 antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of participants with positive malaria test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Changes in the types of microbial resistomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in the quantity of microbial resistomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in the abundance of microbial resistomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Role of medical thoracoscopy on pleural effusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of Participants with Complete Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients failing treatment by Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score change in coolness of e-cigarette conditions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Referrals to ACEs-related services
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Goodman and Baron's acne scar grading system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: 5 point scale for evaluating patient's satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Sensitivity and specificity of the HLA-test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of HLA-DQ2/8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in depression symptom severity via GRID-Hamilton Depression Rating Scale (HAM-D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in depression diagnosis via Structured Clinical Interview for DSM-5 Disorders (SCID)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in depressive symptoms severity via the Quick Inventory of Depressive Symptoms (QIDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in serous detachment height (SDH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neurofilament light chain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Acceptability E-Scale (AES) over 12 months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Yearly incidence of drowning incidents
Endpoint domain: Mortality/survival
Primary endpoint: Fatal to non-fatal drowning ratio
Endpoint domain: Mortality/survival
Primary endpoint: Biomarker levels for Parkinson's diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Harmonic to noise ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Percentage of Participants with Point Prevalent Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Scores on the Fagerstrom Test for Nicotine Dependence (FTND)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Scores on the Beck Depression Inventory (BDI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Eyelid contraction threshold under brightness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain activation (BOLD signal)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pulmonary arterial mean pressure/Cardiac Output (PA/CO) at peak exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Dynamic residual tibia kinematics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic skin deformation of the residual limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of prescription of anticoagulation at 90 days
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Frequency of major bleeding at 6 months
Endpoint domain: Adverse events/effects
Primary endpoint: CD8 TILs density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in body mass index/BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Functional Disability Scale for Ankle (FADI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Safety and tolerability of EXG001-307
Endpoint domain: Adverse events/effects
Primary endpoint: Severe treated hemorrhagic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of mean oral nutritional supplement consumed per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peri-implant disease resolution at 6 month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peri-implant disease resolution at 12 month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of guideline-consistent and personalized EBM recommendations
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Wound healing period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-care Skills
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reliability of SCALA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Airway Obstruction Relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cumulative rate of MAVE
Endpoint domain: Mortality/survival
Primary endpoint: Rate of hemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Fine Motor skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WHODAS 2.0 (World Health Organization Disability Assessment Schedule)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Local Relapse Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Regional Relapse Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Distant Metastases Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: 6-month buprenorphine maintenance treatment retention
Endpoint domain: Mortality/survival
Primary endpoint: Change from Screening in Subjective Opiate Withdrawal Scale (SOWS) at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Screening in Opioid Craving Scale (OCS) at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SLN detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Outcomes of percutaneous inserted PD catheters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Catastrophic Expenditure
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Azithromycin bioavailability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety evaluation of Azithromycin Oleogel
Endpoint domain: Adverse events/effects
Primary endpoint: Concentration of oral dysbiosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of xerostomia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life rate
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Area under the plasma glucose-time curve at steady concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes